- Home
- SNT vs VERU Comparison
SNT vs VERU Comparison
Compare SNT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- VERU
- Stock Information
- Founded
- SNT 1965
- VERU 1971
- Country
- SNT Canada
- VERU United States
- Employees
- SNT N/A
- VERU N/A
- Industry
- SNT Telecommunications Equipment
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- VERU Health Care
- Exchange
- SNT Nasdaq
- VERU Nasdaq
- Market Cap
- SNT 95.2M
- VERU 85.5M
- IPO Year
- SNT 1993
- VERU 1990
- Fundamental
- Price
- SNT $4.25
- VERU $3.42
- Analyst Decision
- SNT
- VERU Strong Buy
- Analyst Count
- SNT 0
- VERU 3
- Target Price
- SNT N/A
- VERU $33.33
- AVG Volume (30 Days)
- SNT 56.6K
- VERU 120.2K
- Earning Date
- SNT 11-11-2025
- VERU 08-12-2025
- Dividend Yield
- SNT N/A
- VERU N/A
- EPS Growth
- SNT N/A
- VERU N/A
- EPS
- SNT 0.22
- VERU N/A
- Revenue
- SNT $38,038,000.00
- VERU $16,886,419.00
- Revenue This Year
- SNT N/A
- VERU N/A
- Revenue Next Year
- SNT N/A
- VERU N/A
- P/E Ratio
- SNT $19.96
- VERU N/A
- Revenue Growth
- SNT 12.79
- VERU 337.24
- 52 Week Low
- SNT $1.40
- VERU $2.64
- 52 Week High
- SNT $5.04
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- SNT 43.70
- VERU 43.02
- Support Level
- SNT $4.42
- VERU $3.40
- Resistance Level
- SNT $4.74
- VERU $3.68
- Average True Range (ATR)
- SNT 0.21
- VERU 0.22
- MACD
- SNT -0.01
- VERU 0.08
- Stochastic Oscillator
- SNT 5.77
- VERU 27.78
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.